Oppenheimer Sees 'Favorable Setup' in Biogen (BIIB) on Alzheimer's Dynamics
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Guggenheim Upgrades Biogen (BIIB) to Buy
May 1, 2023 6:10 AM EDTGuggenheim analyst Yatin Suneja upgraded Biogen (NASDAQ: BIIB) from Neutral to Buy with a price target of $350.00 (from $270.00).
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $304.23 yesterday.
... More